Immunological events following chemoimmunotherapy combination of metastatic malignant melanoma (MMM) (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Immunological events following chemoimmunotherapy combination of metastatic malignant melanoma (MMM) (Meeting abstract).

FASEB J; 6(4):A1333 1992. Unique Identifier : AIDSLINE ICDB/93687107
Soubrane C; Mouawad R; Ichen M; Suissa J; Borel C; Weil M; Khayat D; Dept. of Medical Oncology, Pitie-Salpetriere Hosp., Paris, France

Abstract: 16 patients (pts) with MMM were included in this study. They received 100 mg/m2 of cisplatin (CDDP) over 4 hr at days 1 and 28, followed by 18 MIU/m2/day of interleukin-2 (IL2-Eurocetus) in continuous infusion from days 3 to 6, 17 to 21, 31 to 34 and 45 to 49. Alpha interferon (IFN-Roche) 9 MU/day was given sc 3x/wk. Immunological parameters were studied on days 3, 5, 7, 17, 19, 21, 31, 33, 35, 45, 47 and 49. At each IL2 infusion, a severe lymphocytopenia was shown, but 2-3 days after discontinuation of IL2, a lymphocytosis was detected, which was always higher than the pretreatment level. In all cases, a correlation between lymphocytes expressing IL2 receptor and soluble IL2 receptor (sIL2R) level was found. We found a significant change of sIL2R levels between responder (R; n=10) and nonresponder (NR; n=6) pts during the first two courses (p less than 0.005), but no difference from the third course, suggesting that the cells from NR may be slower in becoming stimulated. We also observed a significant correlation (p less than 0.02) in lymphocytes expressing NKH1+ CD16+ between R and NR, only during the third course. Furthermore, no significant change in CD4/CD8 ratio, both at onset and on treatment, was observed between R and NR pts. NK activity was not affected by CDDP treatment, but a significant difference could be shown (p less than 0.05) between healthy volunteers and MMM pts before treatment.

Keywords: Cisplatin/ADVERSE EFFECTS/THERAPEUTIC USE CD4-CD8 Ratio Human Interferon-alpha/ADVERSE EFFECTS/THERAPEUTIC USE Interleukin-2/ADVERSE EFFECTS/THERAPEUTIC USE Leukopenia/CHEMICALLY INDUCED Melanoma/*IMMUNOLOGY/THERAPY Receptors, Interleukin-2/METABOLISM ABSTRACT
930430
M9340829

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .